靶向药物不良反应处理全文.pptVIP

  • 2
  • 0
  • 约6.32千字
  • 约 39页
  • 2026-11-12 发布于重庆
  • 举报

InthephaseIIItrialofsunitinibvsIFN-αforfirst-linetreatmentmRCC,ORRincreasedwithlongersunitinibtreatmentduration1–3ThetabulateddatagivenabovepresentthefindingsforsunitinibandIFN-αfromtheinterimandfinalanalysesofthetrial.1–3Durationoftherapyisgivenasamedianvalue,presentedinmonthsORRwerederivedfromcentralindependentreview,givenaspercentagesand95%confidenceintervalsP-valuesareforthecomparisonofORRbetweensunitinibandIFN-αatthetwotimepointsThesefindingsofgreaterbenefitintermsofORRwithlongerdurationoftrea

文档评论(0)

1亿VIP精品文档

相关文档